DGAP-Media / 2019-05-22 / 07:00
*Probiodrug to attend International Conferences in June 2019*
*HALLE (SAALE), Germany, 22 May 2019* - Probiodrug AG ("Probiodrug",
Euronext: PBD), announces that the company is scheduled to attend the
following conferences:
*(1) *2019 BIO International Convention [1]
June 3-6, 2019, Pennsylvania Convention Center, Philadelphia, PA, USA
*Dr. Ulrich Dauer, CEO, and Dr. Michael Schaeffer, CBO, to attend and host
meetings*
*(2) Biotech CEO Summit Europe*
June 17-19, 2019, Enniskerry, Ireland
*Dr. Ulrich Dauer, CEO, to attend*
###
*For more information, please contact:*
*Probiodrug *
Dr. Ulrich Dauer, CEO
Email: contact@probiodrug.com
*MC Services AG*
Anne Hennecke, Susanne Kutter
Tel: +49 (0) 211 529 252 27
Email: probiodrug@mc-services.eu
*Notes to Editors:
About Probiodrug AG*
Headquartered in Halle (Saale), Germany, Probiodrug AG (Euronext Amsterdam:
PBD) is a clinical stage biopharmaceutical company focused on the
development of novel inhibitors for disease relevant enzymes. The company
has a successful track record in bringing drugs targeted to
post-translational modifying enzymes to the market. Current projects are
focusing on the two isoenzymes of Glutaminyl Cyclase, QPCT and QPCTL. QPCT
is the crucial enzyme for the generation of highly neurotoxic pyroglutamate
species of Abeta. Its inhibition by Probiodrug's lead molecule PQ912 is
currently investigated in clinical Phase 2 trials (SAPHIR) for the treatment
of Alzheimer's disease (AD). Whereas QPCTL has been identified as a
potential target in cancer therapy. Blocking the enzymatic function of QPTCL
by small molecule inhibitors is a novel therapeutic approach in cancer
immunotherapy. Probiodrug has a unique and exceptionally strong patent
position on QPCT and QPCTL inhibitors.
www.probiodrug.com
*About PQ912*
PQ912, is a first in class, highly specific and potent inhibitor of
Glutaminyl Cyclase (QPCT), - the enzyme that catalyses the formation of
highly neurotoxic pGlu species. PQ912 has shown therapeutic effects in AD
animal models. A Phase-1 study in healthy young and elderly volunteers
revealed a dose dependent exposure and showed good safety and tolerability
up to the highest dose resulting in >90% target occupancy in the spinal
fluid. In June 2017, Probiodrug announced top-line data of the Phase-2a
SAPHIR trial of PQ912 and presented the study results at CTAD 2017. Results
strongly support that pGlu species of Abeta are especially neurotoxic and
correlate with AD disease progression. The SAPHIR study provides important
guidance how to move forward with the development of PQ912 as a
disease-modifying drug for AD. Altogether, the results make the program
highly attractive for further development; the company has initiated the
preparation of a Phase 2b core program.
*About Alzheimer's disease*
Alzheimer's disease is a neurological disorder, which is the most common
form of dementia. Today, 50 million people live with dementia worldwide, and
this number is projected to treble to more than 152 million by 2050.
Dementia also has a huge economic impact. Alzheimer's has an estimated,
global societal cost of US$ 1 trillion, and it will become 2 trillion-dollar
disease by 2030. (World Alzheimer Report 2018).
*Glutaminyl-peptide cyclotransferase-like protein (QPCTL)*
Glutaminyl-peptide cyclotransferase-like protein (QPCTL) is a
posttranslational modifying enzyme that is responsible for the pyroglutamate
formation on crucial proteins in the immune response to cancer.
*Cancer immune checkpoint inhibitors*
Checkpoint inhibitor therapy is a novel kind of cancer immunotherapy. The
therapy targets immune checkpoints, key regulators of the immune system that
stimulate or inhibit its actions, which tumors can use to protect themselves
from attacks by the immune system. QPCTL inhibitor therapy can block
inhibitory cancer checkpoints and thereby restore beneficial immune system
functions.
*Forward Looking Statements*
Information set forth in this press release contains forward-looking
statements, which involve a number of risks and uncertainties. The
forward-looking statements contained herein represent the judgment of
Probiodrug AG as of the date of this press release. Such forward-looking
statements are neither promises nor guarantees but are subject to a variety
of risks and uncertainties, many of which are beyond our control, and which
could cause actual results to differ materially from those contemplated in
these forward-looking statements. We expressly disclaim any obligation or
undertaking to release publicly any updates or revisions to any such
statements to reflect any change in our expectations or any change in
events, conditions or circumstances on which any such statement is based.
End of Media Release
Issuer: Probiodrug AG
Key word(s): Advertisement/Communication
2019-05-22 Dissemination of a Press Release, transmitted by DGAP - a service
of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
Language: English
Company: Probiodrug AG
Weinbergweg 22
06120 Halle/Saale
Germany
Phone: +49 (0)345 555 9900
Fax: +49 (0)345 555 9901
E-mail: contact@probiodrug.de
Internet: www.probiodrug.de
ISIN: DE0007921835
WKN: 792183
Listed: Regulated Unofficial Market in Berlin, Frankfurt, Munich,
Stuttgart; Amsterdam
EQS News ID: 813797
End of News DGAP Media
813797 2019-05-22
1: https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=a58f73b76e40c85c20ea2f1eedd4f6f5&application_id=813797&site_id=vwd&application_name=news
(END) Dow Jones Newswires
May 22, 2019 01:00 ET (05:00 GMT)
